

Reference:	FOI.6898.21
Subject:	Neurology patient treatments
Date of Request:	19 September 2021

Requested:

- How many patients have been treated with the following drugs in the past 4 months:
 - Aimovig (erenumab) - any disease
 - Ajovy (fremanezumab) - any disease
 - Emgality (galcanezumab) - any disease
 - Botulinum Toxin (i.e. Botox, Dysport, Xeomin) - for migraine ONLY
- Does the trust either commission or fund Botulinum Toxin treatment and/or anti-CGRP monoclonal antibody treatments (Ajovy, Aimovig, Emgality) for migraine (Y/N)?
- How many patients have been treated in the past 4 months for the following conditions:
 - Chronic migraine (15+ headache days per month)
 - Episodic migraine (4-14 headache days per month)

Response:

Hywel Dda University Health Board (UHB) is unable to provide you with all of the information requested, as it is estimated that the cost of answering your request would exceed the “appropriate limit” as stated in the Freedom of Information and Data Protection (Appropriate Limit and Fees) Regulations 2004. The “appropriate limit” represents the estimated cost of one person spending 18 hours (or 2 ½ working days) in determining whether the UHB holds the information, and locating, retrieving and extracting the information.

In order to provide you with the requested data, the UHB would need to undertake a manual trawl of all neurology patient records, to identify any information that fulfils your request.

The UHB is therefore applying an exemption under Section 12 of the Freedom of Information Act 2000 (FoIA), which provides an exemption from a public authority’s obligation to comply with a request for information where the cost of compliance is estimated to exceed the appropriate limit.

However, under Section 16 of the FoIA, we are required as a public authority, to provide advice and assistance so far as it is reasonable, to individuals who have made a request under FoIA. Therefore, the UHB provides the information it holds for questions 1 and 2 below.

- The UHB provides, within the table below, the number of patients treated for any condition with the listed medications provided at question 1, during the period 1 January to 30 April 2021.

Medication	Number
Aimovig (erenumab)	0
Ajovy (fremanezumab)	9
Emgality (galcanezumab)	0
Botulinum Toxin –	
Botox	84
Dysport	30

2. The UHB confirms that it does fund Botulinum Toxin and anti-CGRP monoclonal antibodies treatments, for migraine, in accordance with National Institute for Health and Care Excellence guidance.
3. Section 12 exemption applied. Please see full exemption explanation above.